Vaccine Platform Articles & Analysis
34 news found
The company has enabled the development of the RNA production equipment and developed a thermostable COVID-19 vaccine and platform which enables distribution across the continent to even the remotest rural communities, an essential part of the collaboration, and is sharing the way this LNP formulation needs to be produced. ...
ByeTheRNA
The low cost and scalability of Lumen’s production platform, coupled with easy, needle-free administration, could greatly expand real-world access to malaria vaccines. ...
The sublingual COVID-19 vaccine uses sublingual mucosal delivery technology to deliver the vaccine to the mucous membrane. ...
CD BioGlyco, a biotechnology company specialized in the field of glycobiology, has developed a series of advanced vaccine development platforms by integrating various advanced technologies to promote the development of glycol-based vaccines. ...
Abera is a biotechnology company with several proprietary vaccine platforms. The company has a vaccine candidate against pneumococcus that is being prepared for clinical phase evaluation and several pre-clinical vaccine candidates against other bacterial and viral infections. ...
Expand CpG 1018 Adjuvant Supply Business for COVID-19 Vaccines Recent Phase 3 clinical data from partnered programs consistently demonstrated the value of CpG 1018 adjuvant across multiple vaccine platforms. ...
In a new study, scientists report that they have successfully freeze-dried a liposome-based liquid vaccine formula that could be developed for potential use in COVID-19 vaccines. ...
Oxford, UK, 16 November 2021: SpyBiotech, a biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces the appointment of Simon Jones as VP of Finance and Operations, and the expansion of its scientific team with four new hires. ...
INOVIO's vaccine candidates do not interfere with or change in any way an individual's own DNA. The potential advantages of INOVIO's vaccine platform include how quickly DNA vaccine candidates can be designed and manufactured; the stability of the vaccine candidates, which do not require freezing in storage and ...
Location: Congress Center Basel – Basel, Switzerland Presentation: Late-stage clinical development of a personalized vaccine platform technology for cancer and COVID-19 When: Wednesday, November 10, 11:50 AM CEST Location: Congress Center Basel – Basel, ...
Angany’s CEO, Dr Louis-Philippe Vézina, is a successful pharma entrepreneur, world renowned for his expertise in the design and production of new generations of vaccines. The company is pursuing a mission initiated in France in 2010 and plans to enter in clinical trials with its first allergy vaccine candidate (allergy to cats) in early 2022, to soon ...
Abera Bioscience AB is a biotechnology company that develops vaccine candidates based on patented vaccine platforms. The latest vaccine platform makes it possible to produce single, or multiple, antigens in so-called protein bodies. Antigens are the pathogen-specific components of vaccines that ...
The award supports a collaboration between POP BIO and the Texas Biomedical Research Institute (Texas Biomed), with the goal of using POP BIO’s next-generation vaccine delivery platform to generate a novel vaccine that seeks to break the cold-chain requirements, and the resulting costs and challenges associated with the need to maintain the ...
Abera intends to attract the leading experts in the field and build a competitive consortium and project for the development of vaccines based on the company’s platforms to attract funding from the EU’s international health call next year. ...
Abera intends to attract the leading experts in the field and build a competitive consortium and project for the development of vaccines based on the company’s platforms to attract funding from the EU’s international health call next year. ...
Abera Bioscience AB (“Abera” or “the Company”) continues to improve its vaccine platform in collaboration with researchers at Vrije Universiteit Amsterdam. ...
“We have deployed Meissa’s AttenuBlock platform to establish a recombinant live attenuated COVID-19 vaccine that is designed to be genetically stable as well as optimized to drive robust and durable immunity,” said Roderick Tang, Ph.D., Chief Scientific Officer and Cofounder of Meissa Vaccines. ...
The patent forms the basis of a new vaccine platform that the company has developed in parallel with existing platforms. ...
Since the discovery of RSV in 1956, no vaccine has been approved for prevention. “We believe that our intranasal live attenuated RSV vaccine candidate, developed on Meissa’s AttenuBlockTM vaccine platform, offers the potential to finally immunize against RSV, which has evaded other vaccine ...
The Article ‘A Total Meltdown‘ highlights how next generation vaccination technologies such as ImplaVax® needle-free, thermally stable unit solid dose vaccination platform could make a material impact on the ease of future deployment and reduce or eliminate the burden of cold chain ...